150 related articles for article (PubMed ID: 28035915)
1. Modulators of IgG penetration through the blood-brain barrier: Implications for Alzheimer's disease immunotherapy.
Finke JM; Banks WA
Hum Antibodies; 2017; 25(3-4):131-146. PubMed ID: 28035915
[TBL] [Abstract][Full Text] [Related]
2. IgG-assisted age-dependent clearance of Alzheimer's amyloid beta peptide by the blood-brain barrier neonatal Fc receptor.
Deane R; Sagare A; Hamm K; Parisi M; LaRue B; Guo H; Wu Z; Holtzman DM; Zlokovic BV
J Neurosci; 2005 Dec; 25(50):11495-503. PubMed ID: 16354907
[TBL] [Abstract][Full Text] [Related]
3. Antibody blood-brain barrier efflux is modulated by glycan modification.
Finke JM; Ayres KR; Brisbin RP; Hill HA; Wing EE; Banks WA
Biochim Biophys Acta Gen Subj; 2017 Sep; 1861(9):2228-2239. PubMed ID: 28624473
[TBL] [Abstract][Full Text] [Related]
4. Fusion antibody for Alzheimer's disease with bidirectional transport across the blood-brain barrier and abeta fibril disaggregation.
Boado RJ; Zhang Y; Zhang Y; Xia CF; Pardridge WM
Bioconjug Chem; 2007; 18(2):447-55. PubMed ID: 17315944
[TBL] [Abstract][Full Text] [Related]
5. Neonatal Fc receptor (FcRn): a novel target for therapeutic antibodies and antibody engineering.
Wang Y; Tian Z; Thirumalai D; Zhang X
J Drug Target; 2014 May; 22(4):269-78. PubMed ID: 24404896
[TBL] [Abstract][Full Text] [Related]
6. Reducing neonatal Fc receptor binding enhances clearance and brain-to-blood ratio of TfR-delivered bispecific amyloid-β antibody.
Schlein E; Andersson KG; Dallas T; Syvänen S; Sehlin D
MAbs; 2024; 16(1):2339337. PubMed ID: 38634473
[TBL] [Abstract][Full Text] [Related]
7. Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels.
Vaccaro C; Zhou J; Ober RJ; Ward ES
Nat Biotechnol; 2005 Oct; 23(10):1283-8. PubMed ID: 16186811
[TBL] [Abstract][Full Text] [Related]
8. Re-engineering therapeutic antibodies for Alzheimer's disease as blood-brain barrier penetrating bi-specific antibodies.
Pardridge WM
Expert Opin Biol Ther; 2016 Dec; 16(12):1455-1468. PubMed ID: 27572805
[TBL] [Abstract][Full Text] [Related]
9. Reengineering biopharmaceuticals for targeted delivery across the blood-brain barrier.
Pardridge WM; Boado RJ
Methods Enzymol; 2012; 503():269-92. PubMed ID: 22230573
[TBL] [Abstract][Full Text] [Related]
10. Efflux of monoclonal antibodies from rat brain by neonatal Fc receptor, FcRn.
Cooper PR; Ciambrone GJ; Kliwinski CM; Maze E; Johnson L; Li Q; Feng Y; Hornby PJ
Brain Res; 2013 Oct; 1534():13-21. PubMed ID: 23978455
[TBL] [Abstract][Full Text] [Related]
11. In vivo targeting of antibody fragments to the nervous system for Alzheimer's disease immunotherapy and molecular imaging of amyloid plaques.
Poduslo JF; Ramakrishnan M; Holasek SS; Ramirez-Alvarado M; Kandimalla KK; Gilles EJ; Curran GL; Wengenack TM
J Neurochem; 2007 Jul; 102(2):420-33. PubMed ID: 17596213
[TBL] [Abstract][Full Text] [Related]
12. Plasma Pharmacokinetics of High-Affinity Transferrin Receptor Antibody-Erythropoietin Fusion Protein is a Function of Effector Attenuation in Mice.
Sun J; Boado RJ; Pardridge WM; Sumbria RK
Mol Pharm; 2019 Aug; 16(8):3534-3543. PubMed ID: 31199881
[TBL] [Abstract][Full Text] [Related]
13. Fc Engineering of Human IgG1 for Altered Binding to the Neonatal Fc Receptor Affects Fc Effector Functions.
Grevys A; Bern M; Foss S; Bratlie DB; Moen A; Gunnarsen KS; Aase A; Michaelsen TE; Sandlie I; Andersen JT
J Immunol; 2015 Jun; 194(11):5497-508. PubMed ID: 25904551
[TBL] [Abstract][Full Text] [Related]
14. Anti-amyloid beta protein antibody passage across the blood-brain barrier in the SAMP8 mouse model of Alzheimer's disease: an age-related selective uptake with reversal of learning impairment.
Banks WA; Farr SA; Morley JE; Wolf KM; Geylis V; Steinitz M
Exp Neurol; 2007 Aug; 206(2):248-56. PubMed ID: 17582399
[TBL] [Abstract][Full Text] [Related]
15. FcRn: the neonatal Fc receptor comes of age.
Roopenian DC; Akilesh S
Nat Rev Immunol; 2007 Sep; 7(9):715-25. PubMed ID: 17703228
[TBL] [Abstract][Full Text] [Related]
16. Gene delivery of a modified antibody to Aβ reduces progression of murine Alzheimer's disease.
Elmer BM; Swanson KA; Bangari DS; Piepenhagen PA; Roberts E; Taksir T; Guo L; Obinu MC; Barneoud P; Ryan S; Zhang B; Pradier L; Yang ZY; Nabel GJ
PLoS One; 2019; 14(12):e0226245. PubMed ID: 31887144
[TBL] [Abstract][Full Text] [Related]
17. Investigation of the role of FcγR and FcRn in mAb distribution to the brain.
Abuqayyas L; Balthasar JP
Mol Pharm; 2013 May; 10(5):1505-13. PubMed ID: 22838637
[TBL] [Abstract][Full Text] [Related]
18. Antibody-mediated immunotherapy for Alzheimer's disease.
Solomon B
Curr Opin Investig Drugs; 2007 Jul; 8(7):519-24. PubMed ID: 17659471
[TBL] [Abstract][Full Text] [Related]
19. Brain Shuttle Antibody for Alzheimer's Disease with Attenuated Peripheral Effector Function due to an Inverted Binding Mode.
Weber F; Bohrmann B; Niewoehner J; Fischer JAA; Rueger P; Tiefenthaler G; Moelleken J; Bujotzek A; Brady K; Singer T; Ebeling M; Iglesias A; Freskgård PO
Cell Rep; 2018 Jan; 22(1):149-162. PubMed ID: 29298417
[TBL] [Abstract][Full Text] [Related]
20. Brain Disposition of Antibody-Based Therapeutics: Dogma, Approaches and Perspectives.
Kouhi A; Pachipulusu V; Kapenstein T; Hu P; Epstein AL; Khawli LA
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34208575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
